Moderna Stock Doubles on Cancer Breakthrough: Here’s What It Means

In brief

• Moderna (MRNA) jumped ~131% Wednesday after the Phase 3 INTerpath-001 trial of intismeran autogene plus Keytruda hit its RFS and DMFS endpoints in resected melanoma.
• Intismeran autogene is a personalized mRNA neoantigen therapy built from each patient's tumor mutations, paired with Merck's Keytruda immunotherapy.
• Traders shorting Moderna faced ~$4.8B in mark-to-market losses as the stock doubled; short interest sat at 13.5% of free float.

Moderna's personalized mRNA cancer shot cleared its first Phase 3 readout, and the market reacted like it had won more than a trial.

Shares of Moderna, which trades as MRNA, surged about 131% on Wednesday, more than doubling to near $148 after touching $163 intraday, a record one-day jump. Merck (MRK), the larger partner that sells Keytruda, also spiked on the news.

The companies said the Phase 3 INTerpath-001 trial of intismeran autogene plus Keytruda met its recurrence-free and distant-metastasis-free survival goals in patients whose stage IIB–IV melanoma had been surgically removed.

It's the first positive Phase 3 result for a personalized neoantigen therapy, and the first for an mRNA-based cancer treatment.

What the therapy actually does

Intismeran autogene (also called V940 or mRNA-4157) isn't a mass-produced vial. Doctors sequence a patient's tumor, map its unique mutations, and the mRNA teaches the body to manufacture neoantigens—protein fragments the immune system learns to spot and attack.